ATC/DDD classification (temporary)

191 WHO Drug Information Vol. 29, No. 2, 2015 ATC/DDD classification The Anatomical Therapeutic Chemical (ATC) classification system and the Defined Daily Dose (DDD) as a measuring unit are tools for exchanging and comparing data on drug use at international, national or local levels. The ATC/DDD system has become the gold standard for international drug utilization research. It is maintained by the WHO Collaborating Centre for Drug Statistics Methodology in Oslo, Norway. Visit www.whocc.no/ for more information. ATC/DDD classification (temporary) The following ATC codes and DDDs were agreed at the meeting of the WHO International Working Group for Drug Statistics Methodology in March 2015. Comments or objections to the decisions from the meeting should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology (whocc@fhi.no) before 1 September 2015. If no objections are received before this date, the new ATC codes and DDDs will be considered final and will be included in the January 2016 version of the ATC/DDD Index. New ATC 5th level codes: ATC level name/INN ATC code anthrax immunoglobulin J06BB19 armodafinil N06BA13 atorvastatin, amlodipine and perindopril C10BX11 begelomab L04AA35 brexpiprazole N05AX16 brodalumab L04AC12 cediranib L01XE32 ceftazidime, combinations J01DD52 conjugated estrogens and bazedoxifene G03CC07 drisapersen M09AX04 droxidopa C01CA27 dulaglutide A10BX14 emtricitabine, tenofovir alafenamide and rilpivirine J05AR19 ibuprofen R02AX02 idarucizumab V03AB37 ivacaftor and lumacaftor R07AX30 ixazomib L01XX50 lesinurad M04AB05 necitumumab L01XC22 palbociclib L01XE33 Continued/ ATC/DDD classification WHO Drug Information Vol. 29, No. 2, 2015 192 New ATC 5th level codes, continued: ATC level name/INN ATC code pantoprazole, amoxicillin, clarithromycin and metronidazole A02BD11 perindopril and bisoprolol C09BX02 ramucirumab L01XC21 reslizumab R03DX08 salmeterol and budesonide R03AK12 saxagliptin and dapagliflozin A10BD21 selexipag B01AC27 sodium benzoate A16AX11 tivozanib L01XE34 valsartan and lercanidipine C09DB08 valsartan and sacubitril C09DX04 zoledronic acid, calcium and colecalciferol, sequential M05BB08 Change of ATC codes: ATC level name/INN Previous ATC code New ATC code calcium acetate1) A12AA12 V03AE07 ferric citrate B03AB06 V03AE08 1) Previous ATC level name: calcium acetate anhydrous New DDDs: ATC level name/INN DDD unit Adm.R* ATC code alogliptin 25 mg O A10BH04 armodafinil 0.15 g O N06BA13 artesunate 0.28 g P P01BE03 clenbuterol 40 mcg O R03CC13 colistin 3 MU Inhal. powder J01XB01 dasabuvir 0.5 g O J05AX16 dulaglutide 0.16 mg P A10BX14 eliglustat 0.168 g O A16AX10 empagliflozin 17.5 mg O A10BX12 teduglutide 5 mg P A16AX08 tofacitinib 10 mg O L04AA29 umeclidinium bromide 55 mcg2) Inhal. powder R03BB07 * Administration Route: O=oral; P=parenteral 2) Refers to umeclidinium, delivered dose Change of DDDs: ATC level name/INN Previous DDD New temporary DDD ATC code DDD unit Adm.R* DDD unit Adm.R* apixaban 5 mg O 10 mg O B01AF02 dabigatran etexilate 0.22 g O 0.3 g O B01AE07 human menopausal gonadotrophin 30 U P 75 U P G03GA02 rivaroxaban 10 mg O 20 mg O B01AF01 * Administration Route: O=oral; P=parenteral æ Temporary 193 WHO Drug Information Vol. 29, No. 2, 2015 ATC/DDD classification ATC/DDD classification (final) The following ATC codes, DDDs and alterations were agreed at the meeting of the WHO International Working Group for Drug Statistics Methodology in October 2014. These are considered as final and will be included in the January 2016 version of the ATC/DDD Index. New ATC 5th level codes: ATC level name/INN ATC code asfotase alfa A16AB13 ataluren M09AX03 atazanavir and cobicistat J05AR15 belinostat L01XX49 benzyl alcohol P03AX06 blinatumomab L01XC19 brivaracetam N03AX23 bupropion and naltrexone A08AA62 ceftolozane and enzyme inhibitor J01DI54 dasabuvir J05AX16 dasabuvir, ombitasvir, paritaprevir and ritonavir J05AX66 drospirenone G03AC10 efinaconazole D01AC19 emtricitabine and tenofovir alafenamide J05AR17 emtricitabine, tenofovir alafenamide, elvitegravir and cobicistat J05AR18 insulin degludec and liraglutide A10AE56 isavuconazole J02AC05 lamivudine and raltegravir J05AR16 lenvatinib L01XE29 luliconazole D01AC18 nemonoxacin J01MB08 nintedanib L01XE31 nivolumab L01XC17 obeticholic acid A05AA04 octenidine R02AA21 olodaterol and tiotropium bromide R03AL06 ombitasvir, paritaprevir and ritonavir J05AX67 papillomavirus (human types 6, 11, 16, 18, 31, 33, 45, 52, 58) J07BM03 pembrolizumab L01XC18 pitolisant N07XX11 rosuvastatin and valsartan C10BX10 sebelipase alfa A16AB14 sirolimus S01XA23 smallpox, live attenuated J07BX01 sofosbuvir and ledipasvir J05AX65 sonidegib L01XX48 tasimelteon N05CH03 ATC/DDD classification WHO Drug Information Vol. 29, No. 2, 2015 194 New DDDs: ATC level name/INN DDD unit Adm. R.* ATC code abarelix 3.6 mg P L02BX01 albiglutide 5.7 mg P A10BX13 aripiprazole 13.3 mg P depot N05AX12 azilsartan medoxomil 40 mg O C09CA09 canagliflozin 0.2 g O A10BX11 cobicistat 0.15 g O V03AX03 daclatasvir 60 mg O J05AX14 dexmethylphenidate 15 mg O N06BA11 lomitapide 40 mg O C10AX12 loxapine 9.1 mg1) Inhal. powder N05AH01 misoprostol 0.2 mg V2) G02AD06 olodaterol 5 mcg Inhal. sol R03AC19 peginterferon beta-1a 8.9 mcg P L03AB13 riociguat 4.5 mg O C02KX05 siltuximab 37 mg P L04AC11 simeprevir 0.15 g O J05AE14 sucroferric oxyhydroxide 1.5 g O V03AE05 vedolizumab 5.4 mg P L04AA33 * Route of administration (Adm.R): O=oral; P=parenteral; V=vaginal; Inhal=inhalation 1) delivered dose 2) vaginal insert, refers to the content of one vaginal insert æ Final